FOXP1 and marginal zone lymphoma: Interestingly, subsequent studies postulated an oncogenic role of FOXP1 in lymphoma, particularly in an activated B-cell subtype of diffuse large B-cell lymphoma (ABC-DLBCL) with a poor clinical outcome [18]–[23], and extranodal marginal zone lymphoma (MZL), where a strong expression of FOXP1 protein correlates with a risk of a high grade transformation [24]–[27].